• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Seminars in cancer biology >Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
【24h】

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

机译：对黑素瘤的特异性T细胞反应的动态变化与IL-2给药有关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interleukin 2 (IL-2) is a promising immunotherapeutic agent for the treatment of metastatic melanoma and renal cell carcinoma. Systemic administration of high dose IL-2 produces objective responses in up to 25% of melanoma patients, and a low but significant proportion of these patients experience durable responses. Nevertheless, the cells and molecules responsible for induction of tumor regression over the course of IL-2 treatment remain unknown. New strategies in tumor immunotherapy have evolved over the past decade as a consequence of significant progress in the field, in particular with respect to the characterization of peptide epitopes derived from tumor associated antigens, and the role of antigen presenting cells in the initiation of cellular immune responses. Alongside with these factual as well as conceptual advances, new methods have been developed to monitor and characterize anti-tumor T cell responses in cancer patients. Application of these tools to dissect anti-tumor responses has demonstrated that various immune therapeutic approaches can induce powerful systemic anti-tumor cytotoxic T lymphocyte (CTL) responses. However, only limited efforts have been made to use present days tool to analyze anti-tumor immune responses in patients treated with IL-2 based immunotherapy. We have examined CTL responses against known tumor antigens in melanoma patients over the course of IL-2 based immunotherapy (electrochemotherapy). Surprisingly, anti-tumor CTL responses significantly declined upon initiation of therapy, but reappeared when IL-2 administration was paused. Molecular analyses of the clonotypic composition of responding T cells demonstrated that new clones emerged over the course of treatment, and that tumor-specific T cells that had left the peripheral blood could subsequently be detected at the tumor site. These data provide new insight into the biological actions of IL-2 and highlight the difficulties associated with the monitoring of anti-tumor immune responses. This underlines the importance of frequent sampling of blood and tumor biopsies to be analyzed with a combination of state of the art technologies in order to gain detailed information on the interactions between cancer cells and cells of the immune system.
机译：白介素2（IL-2）是用于治疗转移性黑色素瘤和肾细胞癌的一种有前途的免疫治疗剂。高剂量IL-2的全身给药可在多达25％的黑色素瘤患者中产生客观反应，而这些患者中只有极低但显着比例的患者会产生持久反应。然而，在IL-2治疗过程中负责诱导肿瘤消退的细胞和分子仍然未知。由于该领域的重大进展，尤其是在表征肿瘤相关抗原衍生的肽表位以及抗原呈递细胞在细胞免疫启动中的作用方面，肿瘤免疫疗法的新策略在过去十年中得到了发展。回应。除了这些事实以及概念上的进步外，还开发了新的方法来监测和表征癌症患者的抗肿瘤T细胞反应。这些工具用于剖析抗肿瘤反应已证明各种免疫治疗方法可诱导强大的全身性抗肿瘤细胞毒性T淋巴细胞（CTL）反应。但是，仅有限的努力来使用当今的工具来分析以IL-2为基础的免疫疗法治疗的患者的抗肿瘤免疫反应。我们已经检查了基于IL-2的免疫疗法（电化学疗法）过程中黑色素瘤患者对已知肿瘤抗原的CTL反应。出人意料的是，抗肿瘤的CTL反应在开始治疗后显着下降，但在暂停IL-2给药后再次出现。对反应性T细胞的克隆型组成的分子分析表明，在治疗过程中出现了新的克隆，并且随后可以在肿瘤部位检测到离开外周血的肿瘤特异性T细胞。这些数据提供了对IL-2生物学作用的新见解，并突出了与监测抗肿瘤免疫反应相关的困难。这强调了经常抽取血液和肿瘤活检样本进行分析的重要性，这些样本需要结合最先进的技术进行分析，以便获得有关癌细胞与免疫系统细胞之间相互作用的详细信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号